

Ekso Bionics CEO Nathan Harding to be Interviewed Live Today on "Varney & Co." on Fox Business Network

RICHMOND, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, today announced that Nathan Harding, Chief Executive Officer, will be interviewed live this morning by Stuart Varney on the Fox Business Network program, "Varney & Co." Details of the broadcast are as follows:

Date: Tuesday August 4th, 2015

Start Time: 10:35 am EDT

Network: Fox Business Network

Show: Varney & Co.

Host: Stuart Varney

Live television stream: [Click here to watch live](#)

Harding will share updates on how Ekso Bionics' leading exoskeleton technology continues to change peoples' lives. Highlights will include continued growth in multi-unit customers, a review of what thought leaders in rehabilitation technology shared at the first ever Exoskeleton Clinical Science Organization, as well as how the efforts to commercialize the company's industrial exoskeleton are progressing. Harding will also share his outlook for the year ahead.

To learn more about Stuart Varney and "Varney & Co.", please visit:

<http://www.foxbusiness.com/on-air/varney-co/index.html>

About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com

Facebook: www.facebook.com/eksobionics

Twitter: [@eksobionics](https://twitter.com/eksobionics)

YouTube: <https://www.youtube.com/user/EksoBionics/>

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com. The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:

Heidi Darling, Director of Marketing Communications

Phone: 510-984-1761 x317

E-mail: hdarling@eksobionics.com

Investor Contact:

Chad Rubin, Senior Vice President

Phone: 646-378-2947

E-mail: crubin@troutgroup.com

Source: Ekso Bionics